Epigenetic Regulators in Cancer: Comprehensive Notes

Epigenetic Regulation in Cancer: Comprehensive Notes

  • Cancer genome analysis has identified genetically altered genes that drive tumorigenesis and shaped our understanding of pathways and gene functions in normal and cancer tissues.

    • Identifying cancer genes is a prerequisite for biomarkers and targeted therapies in cancer.
    • Approaches evolved from candidate-gene studies to genome-wide screening, propelled by consortia like ICGC and TCGA and the rise of next-generation sequencing.
    • There is growing recognition that alterations in epigenetic regulation are as important as alterations in the genomic coding information itself, contributing to tumorigenesis by reprogramming gene expression programs.

  • Epigenetics in cancer: a framework

    • Epigenetic modifications of DNA and histones, and/or alterations in chromatin-remodeling, act as switches that turn gene expression on/off or modulate expression levels.
    • Major epigenetic players operate as:
    • Writers: enzymes that add a modification
    • Editors: enzymes that remove or alter a modification
    • Readers: proteins that mediate interactions with the modification and recruit downstream effectors
    • This trio governs DNA methylation, histone marks, and chromatin states (Figure 1).
    • DNA methylation changes (5-methylcytosine, 5mC) have been extensively studied in cancer, followed by histone modifications. Epigenomic deregulation is pervasive in cancers.
    • Epigenetic profiling is increasingly integrated with genetic profiling to understand cancer genomes, though integration has lagged behind the genetic side due to methodological and mechanistic complexities.
    • Recent advances include cancer-specific mutations in epigenetic regulators and high-throughput assays to measure genome-wide epigenetic patterns and their links to genetic changes.

  • Key terms and definitions

    • Epigenetic modifications: DNA and histone modifications that regulate gene expression without changing the DNA sequence; these are transmitted through cell divisions.
    • Epigenome: the complete set of epigenetic modifications across the genome in a tissue.
    • CpG island methylator phenotype (CIMP): Enrichment of methylation in GC-rich promoter regions across tumors, used to define cancer subtypes.
    • Promoter methylation: Hyper methylation of CpG islands in promoters is commonly associated with gene silencing of tumor suppressors.
    • PMDs (Partially Mounded Domains): Large genomic regions with partial DNA methylation that correlate with repressive histone marks and gene silencing; tissue-specific and sometimes align with lamina-associated domains (LADs).
    • 5mC → 5hmC → 5fC → 5caC: sequential oxidation steps in active DNA demethylation mediated by TET enzymes; ultimately excised and repaired to restore unmethylated cytosine.
    • 2-HG (2-hydroxyglutarate): oncometabolite produced by mutant IDH1/2 that inhibits TETs and Jumonji demethylases, leading to global epigenetic reprogramming.

  • Enzymatic classes involved in DNA and histone modifications (Figure 1 overview)

    • Writers: establish a mark on DNA or histone tails (e.g., DNMTs, HMTs, HATs).
    • Editors: modify or revert a modification (e.g., demethylases like KDMs, histone demethylases; TDG in base excision repair pathways).
    • Readers: recognize and mediate effects of modifications by engaging protein complexes (e.g., BRD-containing bromodomain readers).
    • Examples summarized in Figure 1:
    • DNA modifications: writers include DNMTs (DNMT1, DNMT3A, DNMT3B, DNMT3L); editors include TDG (thymine–DNA glycosylase) in demethylation pathways; readers include proteins with methyl-binding domains.
    • Histone modifications: writers include HMTs (e.g., EZH2, DOT1L, MLL family, PRMTs); editors include HDACs and KDMs; readers include bromodomain proteins and other chromatin readers.
    • Key substrate classes: DNA methylation (5mC) and histone modifications (acetylation, methylation, phosphorylation) with corresponding writers/editors/readers.

  • DNA methylation in cancer: global patterns and subdivisions

    • DNA methylation alterations in cancer include both promoter hypermethylation (gene silencing) and global hypomethylation (genome-wide loss affecting repetitive elements, gene bodies, and regulatory regions).
    • Hypermethylation of CpG island promoters is linked to silencing of tumor suppressor genes involved in apoptosis, cell cycle regulation, migration, and DNA repair.
    • Global hypomethylation contributes to chromosomal instability, including translocations and deletions.
    • The methylome is reorganized in cancer and interacts with histone modifications to shape chromatin states.
    • Methylome profiling reveals 2,000–3,000 aberrantly methylated promoter regions per cancer genome, mostly hypermethylated, yet far more genes are epigenetically silenced than are mutated genetically in many cancers.
    • The nonrandom patterns of aberrant CpG island methylation indicate targeted mechanisms; tumor types show distinct methylation signatures, reflecting cell of origin and tissue context.
    • PMDs associated with broad hypomethylated regions correlate with repressive histone marks and gene silencing, and can align with nuclear lamina-associated domains (LADs).
    • The interplay between DNA methylation and histone modifications determines the global chromatin state and transcriptional output. Hyper methylated promoters of lineage-commitment genes in cancer often exhibit bivalent chromatin (H3K4me3 and H3K27me3) in normal multipotent cells, indicating a poised state in development that can be destabilized in cancer.
    • WGBS and related profiling approaches reveal tissue-specific PMD patterns and the overall hypomethylation state in cancer.

  • Global epigenetic alterations in cancer: profiling technologies and implications

    • Advancements in profiling technologies have improved precision and scope of analysis for epigenetic changes (Figure 2).
    • Early genome-wide studies highlighted nonrandom methylation patterns and tumor-type-specific methylomes, enabling tumor subtyping and prognosis.
    • High-throughput approaches include WGBS, RRBS, MeDIP-based methods, Infinium arrays, and other genome-wide platforms to map DNA methylation and histone modifications.
    • The timeline of technologies shows progression from promoter/limited CpG screens to genome-wide, base-resolution methylome mapping and chromatin-state profiling.

  • Mutations in regulators of the epigenome: scope and impact

    • Large-scale sequencing has uncovered mutations in ~700 epigenetic enzymes across cancers, including components of chromatin packaging, DNA methylation/demethylation, histone modification, and chromatin remodeling pathways (Figure 3a).
    • Categories of mutated epigenetic regulators (examples):
    • DNA modification: DNMT family (DNMT1, DNMT3A, DNMT3B, DNMT3L), TET family (TET1–3), AICDA, TDG, IDH1/IDH2, MGMT.
    • Histone modification: writers (EZH2, DNMTs, DOT1L, MLLs, SETDs), editors (KDMs like KDM1A/LSD1, HDACs), readers (BRD proteins, CHDs, MBD family).
    • Chromatin remodeling: SWI/SNF complexes (ARID1A, SMARCA4/BRG1), CHD remodelers, ISWI, INO80 family; these often act as tumor suppressors.
    • The distribution and frequencies of mutations vary by tissue type (as summarized in Figure 3b), with some cancers showing high frequencies in epigenetic regulators. These data come from consortia (ICGC, TCGA) and reflect both driver mutations and background mutational processes.
    • Key mechanistic themes:
    • Mutations in DNA methylation machinery (e.g., DNMT3A, TET2) disrupt normal methylation dynamics and re-pattern the methylome, promoting oncogenic programs.
    • TET mutations and IDH mutations often converge on a hypermethylation phenotype via 2-HG production, inhibiting TET and Jumonji demethylases.
    • Histone-modifying enzymes alter chromatin states globally or at target loci, shifting transcriptional programs toward oncogenesis or impaired differentiation.
    • Chromatin remodelers alter nucleosome positioning and higher-order chromatin structure, affecting large genome regions and multiple pathways simultaneously.

  • DNA methylation pathways: writers, editors, and demethylation

    • DNA methylation machinery:
    • De novo methylation: extDNMT3A,extDNMT3B,extDNMT3Lext{DNMT3A}, ext{DNMT3B}, ext{DNMT3L} using the methyl donor extSAMext{SAM} (S-adenosyl-L-methionine).
    • Maintenance methylation: extDNMT1ext{DNMT1} preserves methylation during replication.
    • Demethylation pathways:
    • Active demethylation via TET enzymes: 5mC<br/>ightarrow5hmC<br/>ightarrow5fC<br/>ightarrow5caC5mC <br /> ightarrow 5hmC <br /> ightarrow 5fC <br /> ightarrow 5caC, followed by excision by TDG and base-excision repair to restore unmethylated cytosine.
    • Alternative active demethylation routes include deamination and repair-based processes.
    • Key interactions and consequences:
    • 5mC is a target of TET enzymes (TET1/2/3) enabling oxidation to 5hmC, 5fC, and 5caC.
    • 2-HG produced by mutant IDH1/2 inhibits TETs and Jumonji-KDMs, promoting a hypermethylation phenotype and altered histone marks.
    • Mutations and cancer implications:
    • DNMT3A mutations are common in AML (and found in some solid tumors); they often reduce catalytic activity or alter histone interactions, leading to global changes in gene expression (including HOX genes and IDH1).
    • TET2 mutations occur in myeloproliferative neoplasms and myelodysplastic syndromes; TET3/TET1 alterations are less common but have context-specific roles.
    • IDH1/IDH2 dominant-negative mutations produce 2-HG, linked to a broad epigenetic reprogramming phenotype; IDH1 R132H is associated with distinct methylation patterns and, in glioblastoma, a relatively better prognosis than IDH-wild-type tumors in some settings.
    • IDH1/IDH2 mutations are often mutually exclusive with TET2 mutations, consistent with convergent disruption of TET/TET-like activity via 2-HG.

  • Box 1 (epigenetic effects of H3.3-K27M, H3.3-G34R/V and IDH1-R132H in glioblastoma)

    • H3.3-K27M mutation
    • Targeted enzyme: EZH2 (PRC2) and broader effects on polycomb signaling.
    • Global effect: loss of H3K27me3; redistribution of H3K27me3 and H3K4me3 leading to a bivalent chromatin state that resembles a poised developmental condition.
    • Developmental bias: neurogenic, mid-to-late cortical development pattern; OLIG2 upregulation in K27M tumors.
    • ALT phenotype observed in both H3.3-K27M and H3.3-G34R/V.
    • Prevalence in pediatric GBM: K27M ~ 19%; G34R ~ 15%; IDH1-R132H < 10%.
    • H3.3-G34R/V mutation
    • Global effect: redistribution of H3K36me3, potentially via SETD2 re-targeting; may upregulate MYCN and other targets.
    • IDH1-R132H mutation
    • Targeted enzymes: KDMs and TETs; effect on 5mC and histone modifications (e.g., H3K9me2/3, H3K27me3, H3K36me3) with broad epigenetic remodeling.
    • Shared consequences and concepts
    • All three mutation types drive epigenetic reprogramming and broad transcriptional changes that promote tumorigenesis, with ALT appearing as a recurring feature.
    • There can be partial overlaps in mechanism (e.g., G34R/V and K27M potentially intersecting via H3K36me3 and H3K27me3 dynamics).
    • The Box emphasizes that mutations in histone variants and enzymes governing epigenetic marks can be highly impactful, often in pediatric glioblastoma, and can interact with other alterations to shape tumor biology.

  • Histone-modifying enzymes and chromatin remodeling in cancer

    • Histone modifying enzymes (HME): writers, editors, and readers govern histone marks that influence transcriptional states.
    • HMTs (e.g., EZH2, MLL family, SETDs) establish methyl marks like H3K27me3 and H3K4me3; alterations can alter gene silencing/activation.
    • KDMs (Lysine demethylases) remove methyl marks (e.g., KDM5A/C; KDM6A/Utx).
    • HDACs remove acetyl marks; HDAC mutations are relatively rare but expression changes and inhibitor sensitivities are clinically relevant.
    • HATs add acetyl groups (e.g., p300/CBP); inhibitors of HATs exist and are in development.
    • Chromatin remodeling complexes (CRCs): SWI/SNF, CHD, ISWI, INO80 families.
    • These ATP-dependent machines reposition, eject, or replace nucleosomes to alter DNA accessibility.
    • Recurrent mutations in CRC components (e.g., ARID1A, SMARCB1) are common across several cancers and often act as tumor suppressors.
    • ARID1A mutations are frequent in ovarian and other cancers; SMARCB1 loss is characteristic of rhabdoid tumors.
    • Nucleosome core histones and chaperones
    • Structural histone mutations (e.g., H3 variants) and chaperones (ATRX/DAXX) influence chromatin deposition and genome stability.
    • ATRX/DAXX mutations associate with ALT in certain tumors (e.g., pancreatic neuroendocrine tumors, GBM).

  • From epigenome deregulation to molecular mechanisms and tumor evolution

    • Nonrandom methylation patterns in tumors suggest targeted or selective mechanisms rather than purely stochastic changes.
    • Targeted mutations in epigenetic regulators can drive global epigenetic reprogramming, contributing to tumorigenesis by silencing tumor suppressors or activating oncogenic programs.
    • Some tumors may acquire global epigenetic deregulation via a single genetic event that perturbs a network of epigenetic regulators, producing widespread transcriptomic consequences.
    • Because epigenetic states are interdependent, mutations in one regulator can propagate through the regulatory network, affecting multiple genes and pathways.
    • Integration of genetic, epigenetic, and transcriptional data is essential to identify driver epigenetic events and to understand how they contribute to tumor biology.

  • Integrative analysis: workflow and tools

    • The proposed workflow integrates three data layers per patient:
    • Genetic alterations (mutations, deletions, translocations, amplifications)
    • Epigenetic alterations (promoter hypermethylation/hypomethylation; regulatory-region changes)
    • Non-coding RNA deregulation and expression changes.
    • Cross-reference genetic and epigenetic alterations with expression to identify frequently altered epigenetic regulators and affected pathways.
    • Validation steps include targeted resequencing of mutations and quantitative DNA methylation analyses.
    • Clustering analyses of epigenetic data help identify tumor subgroups linked to specific epigenetic defects.
    • Functional studies in model systems help decipher mechanism and causality (which epigenetic changes drive tumorigenesis).
    • This integrated approach aims to identify driver epigenetic regulators for biomarker development and novel therapies.
    • Table 1 lists key bioinformatic tools for integrative cancer genome analysis (examples include):
    • cBioPortal for Cancer Genomics, TCGA data portals; PARADIGM; WashU Epigenome Browser; UCSC Cancer Genomics Browser; The Cancer Genome Workbench; EpiExplorer; EpiGRAPH; COSMIC; TCGA data portals; ENCODE resources; ICGC resources; Genomatix; Caleydo; IGV; iCluster/ iClusterPlus; ENCODE data; Integrative microRNA/mRNA expression tools; and more.
    • ENCODE and other large consortia provide reference epigenomic maps essential for contextual interpretation of patient data.

  • Mutations in epigenome regulators: detailed implications

    • DNA modification mutations (examples and consequences):
    • DNMT3A mutations (AML M5 primarily; AML-M4; also seen in some solid tumors). Some variants reduce catalytic activity or alter histone interactions, causing global changes in gene silencing and activation (e.g., HOX genes, IDH1). DNMT3A-mutant tumors show distinct methylation patterns, though validation across cohorts has varied.
    • TET2 mutations are common in myeloid malignancies; mutual exclusivity with IDH1/IDH2 mutations is observed because IDH mutations phenocopy TET loss via 2-HG.
    • IDH1/IDH2 mutations generate 2-HG, inhibiting TETs and KDMs, causing a hypermethylation phenotype and altered histone marks; IDH1 R132H mutation has distinct epigenetic consequences and a potential prognostic impact in gliomas.
    • Histone modification mutations and epigenetic drugs
    • EZH2 mutations: loss-of-function mutations in myeloid malignancies; gain-of-function mutations in certain lymphomas lead to increased H3K27me3; EZH2 activity influences PRC2 target genes and cancer cell proliferation.
    • MLL (KMT2A) alterations: translocations and partial duplications alter H3K4me3 and H3K79 methylation, affecting leukemogenic gene expression programs.
    • HDAC mutations are rare, but expression changes and sensitivity to HDAC inhibitors are clinically relevant; some HDAC mutations may sensitize cells to specific HDAC inhibitors.
    • KDM family mutations and inhibitors: KDM1A/LSD1 inhibitors (e.g., tranylcypromine) show differentiation induction in AML; Jumonji-domain KDM inhibitors are under development.
    • Chromatin remodeling mutations
    • SWI/SNF components (ARID1A, SMARCA4/ BRG1) are frequently mutated across cancers, affecting chromatin accessibility, RB, p53, Polycomb, and stem cell programs; these mutations can act as tumor suppressors and influence large-scale chromatin organization.
    • H3.3/ATRX/DAXX axis in gliomas and beyond
    • H3.3 mutations (H3F3A): K27M and G34R/V substitutions, with strong effects on PRC2 activity and H3K27me3 distribution; these mutations can drive tumorigenesis by reprogramming chromatin states.
    • ATRX and DAXX mutations disrupt H3.3 deposition at subtelomeric regions, associated with ALT in several cancers, including GBM and pancreatic neuroendocrine tumors.

  • From mutations to therapy: epigenetic drugs and targeted approaches

    • Epigenetic therapies aim to reverse gene silencing or aberrant gene activation caused by epigenetic deregulation.
    • DNA methylation inhibitors (DNMT inhibitors):
    • Azacitidine (Vidaza) and Decitabine (Dacogen) are FDA-approved for certain myelodysplastic syndromes (MDS) and AML; used at low doses to reactivate silenced genes and promote anti-tumor effects through epigenetic remodeling.
    • Mechanism: incorporate into DNA during replication and trap DNMTs; lead to transcriptional derepression and differentiation or apoptosis; responses often require multiple cycles.
    • HDAC inhibitors:
    • Vorinostat (SAHA) and Romidepsin (Istodax) approved for CTCL; Panobinostat is a potent pan-HDAC inhibitor with activity in several settings; HDAC inhibitors trigger chromatin opening and gene activation.
    • Targeting specific mutations and enzymes:
    • AGI-5198: a mutant IDH1 inhibitor that blocks mutant IDH1 activity; suppresses growth in glioma models and alters epigenetic marks (notably H3K9 methylation patterns) and differentiation programs; may slow tumor progression in IDH-mutant contexts.
    • DOT1L inhibitors (e.g., EPZ-5676) target histone methylation (H3K79) and show activity in leukemias with MLL rearrangements; EZH2 inhibitors (e.g., GSK126) reduce H3K27me3 and reactivate PRC2-target genes in EZH2-mutant tumors.
    • KDM inhibitors (KDM1A/LSD1, Jumonji-domain KDMs) are in development; inhibition can drive re-expression of differentiation-associated genes.
    • BET bromodomain inhibitors (e.g., JQ1, PFI-1) disrupt BET protein recruitment to acetylated chromatin; suppress MYC/MYCN-driven transcription programs; show activity in AML, MLL-rearranged leukemias, Burkitt lymphoma, neuroblastoma models, and multiple myeloma.
    • Locus-targeted strategies and future directions
    • Beyond global epigenetic remodeling, there is interest in locus-specific epigenetic editing (e.g., using TALENs or other genome engineering tools to recruit chromatin-modifying enzymes to specific loci) to achieve targeted gene regulation with minimized off-target effects.

  • Practical and ethical considerations for epigenetic therapies

    • Epigenetic therapies often exhibit pleiotropic effects because epigenetic regulators control many genes; broad epigenetic reprogramming can affect normal tissue homeostasis and lead to unintended consequences.
    • Tissue specificity and timing of drug delivery are critical to maximize tumor effects while minimizing off-target effects on normal tissues.
    • Combination therapies (epigenetic drugs with chemotherapy, radiotherapy, or targeted agents) may enhance efficacy but require careful assessment of interactions and toxicities.
    • Biomarker-driven patient selection is essential for therapies targeting mutations like IDH1 R132H or EZH2-activating mutations to identify responsive subgroups.
    • The possibility of targeting epigenetic events at specific loci (site-specific chromatin modification) holds promise for reducing global side effects, but practical delivery and specificity challenges remain.

  • Box 2 and Box 1: key takeaways and mechanistic links

    • Box 1 highlights how specific epigenetic mutations in glioblastoma (H3.3-K27M, H3.3-G34R/V, IDH1-R132H) produce characteristic global alterations in histone marks (e.g., H3K27me3, H3K36me3) and DNA methylation patterns, and how these converge on pathways involving PRC2 and TETs.
    • These mutations reveal how a single genetic event can cause widespread epigenetic remodeling and alter developmental gene expression patterns, contributing to tumorigenesis.

  • Summary: integrating genetic and epigenetic data to advance cancer biology and therapy

    • The large-scale discovery of mutations in epigenetic regulators underscores a mechanistic link between genetic alterations and global epigenetic reprogramming in cancer.
    • An integrated approach combining mutation data, epigenetic patterns (DNA methylation, histone modifications), and expression data can identify driver epigenetic regulators and actionable targets.
    • Ongoing development of profiling technologies, computational tools, and locus-specific therapeutic strategies is accelerating the translation of epigenetic understanding into cancer diagnostics and therapies.

  • Important formulas and numerical references (LaTeX format)

    • DNA methylation and methyl donors:
    • De novo and maintenance methylation processes:
      • extDNMT3A/3BextwithdonorextSAM<br/>ightarrowext5mCext(oncytosine)+extSAHext{DNMT3A/3B} ext{ with donor } ext{SAM} <br /> ightarrow ext{5mC} ext{ (on cytosine)} + ext{SAH}
      • extDNMT1extmaintainshemimethylationduringreplicationext{DNMT1} ext{ maintains hemimethylation during replication}
    • Demethylation pathway (TET-mediated):
    • 5mC<br/>ightarrow5hmC<br/>ightarrow5fC<br/>ightarrow5caC<br/>ightarrowextunmethylatedcytosine5mC <br /> ightarrow 5hmC <br /> ightarrow 5fC <br /> ightarrow 5caC <br /> ightarrow ext{unmethylated cytosine}
    • Oncometabolite effect: mutant IDH1/2 produces 2ext−HG2 ext{-HG} that inhibits extTETsext{TETs} and extKDMsext{KDMs}, contributing to DNA hypermethylation and histone methylation changes.
    • Box 1 numerical examples (prevalence in glioblastoma):
    • extK27M(childGBM)<br/>ightarrow19%ext{K27M (child GBM)} <br /> ightarrow 19\%
    • extG34R/V(childGBM)<br/>ightarrow15%ext{G34R/V (child GBM)} <br /> ightarrow 15\%
    • ext{IDH1-R132H (child GBM)}
      ightarrow <10\%
    • extK27M(adultGBM)<br/>ightarrow0%ext{K27M (adult GBM)} <br /> ightarrow 0\%
    • extG34R/V(adultGBM)<br/>ightarrow0%ext{G34R/V (adult GBM)} <br /> ightarrow 0\%
    • extIDH1−R132H(adultGBM)<br/>ightarrow77%ext{IDH1-R132H (adult GBM)} <br /> ightarrow 77\%
    • Box 1 functional outcomes: ALT (alternative lengthening of telomeres) observed with K27M and G34R/V; PRC2 disruption by K27M; H3K36me3 redistribution by G34R/V; bivalent chromatin states and misregulation of lineage-determining genes.

  • Key examples of therapeutic agents (Table 2 highlights)

    • DNMT inhibitors: extazacitidine(Vidaza),extdecitabine(Dacogen)ext{azacitidine (Vidaza)}, ext{decitabine (Dacogen)}; mechanism: DNA incorporation and DNMT trapping; clinical use in MDS and AML; responses often require repeated cycles.
    • HDAC inhibitors: extvorinostat(SAHA),extromidepsin,extpanobinostatext{vorinostat (SAHA)}, ext{romidepsin}, ext{panobinostat}; promote open chromatin and transcriptional activation; approved and in trials across cancers.
    • IDH1/2 inhibitors: extAGI−5198ext{AGI-5198} (mutant IDH1) reduces mutant IDH activity and alters differentiation programs; not directly changing DNA methylation in all contexts but affects histone marks.
    • DOT1L inhibitors: extEPZ−5676ext{EPZ-5676}; target H3K79 methylation; relevant for MLL-rearranged leukemias.
    • EZH2 inhibitors: extGSK126ext{GSK126}; reduce H3K27me3; reactivation of silenced PRC2-target genes in EZH2-mutant contexts.
    • KDM inhibitors: inhibitors of LSD1/KDM1A and Jumonji-domain KDMs in development and cancer therapy.
    • BET inhibitors: extJQ1,extPFI−1ext{JQ1}, ext{PFI-1}; disrupt BET protein recruitment to acetylated chromatin; suppress MYC/MYCN-driven transcription in AML, MLL, neuroblastoma, and other cancers.
    • Other notes: the therapeutic landscape is moving toward tissue- and mutation-specific strategies to reduce off-target effects and improve precision.

  • Practical workflow for studying cancer epigenomics (summary)

    • Start with cataloging epigenetic enzymes (writers/editors/readers) involved in establishing epigenetic patterns.
    • For each patient: catalog genetic alterations, epigenetic alterations, and non-coding RNA deregulation; cross-reference with expression data.
    • Identify recurrently altered epigenetic regulators and implicated pathways; cluster tumors by epigenetic profiles to identify subtypes.
    • Validate candidate drivers with targeted sequencing and DNA methylation analyses in model systems; perform functional assays to elucidate mechanism.
    • Use integrative tools and reference epigenomes (ENCODE/ROADMAP) to interpret patient data and guide biomarker and therapeutic development.

  • Connections to broader themes

    • The interplay between genetics and epigenetics is central to cancer biology; perturbations in epigenetic regulators can cause widespread changes in gene expression and cellular phenotype.
    • Epigenetic deregulation can act both as a primary driver of tumorigenesis and as a mechanism that cooperates with genetic mutations in shaping tumor behavior.
    • Understanding epigenetic alteration networks provides a framework for novel biomarkers and targeted therapies, including locus-specific interventions and combination strategies.

  • References to numeric and conceptual details for exam-ready recall

    • Epigenetic writer/editor/reader framework (Figure 1): classes of enzymes and examples across DNA and histone modifications.
    • Global methylome features in cancer: hypermethylation of promoter CpG islands; global hypomethylation and PMDs; bivalent promoters in development and cancer; lamina-associated domains linkage.
    • DNA methylation machinery mechanics: DNMT1 (maintenance), DNMT3A/3B (de novo); SAM as methyl donor; TDG-mediated demethylation; BER/NER involvement in active demethylation.
    • TET-TET2 relationships with IDH mutations and 2-HG as a functional inhibitor; mutual exclusivity patterns in AML and glioblastoma.
    • H3.3 mutations (K27M, G34R/V) and their broad impact on histone marks and gene expression; ALT phenotype; developmental lineage biases in pediatric GBM.
    • Chromatin remodeling and CRCs: SWI/SNF (ARID1A), SMARCB1; role in RB/p53 signaling and higher-order chromatin architecture.
    • Epigenetic therapeutics landscape: DNMT inhibitors, HDAC inhibitors, mutant IDH inhibitors, DOT1L/EZH2 inhibitors, KDM/BET inhibitors; rationale for use and potential toxicities.
    • Integrative analysis is essential for translating epigenetic insights into clinical advances, including biomarker discovery and targeted therapy development.